Novo Plunges as Investors Seek More Robust Sales Targets

Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer…

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.